Luye Pharma (HKG:2186) received U.S. FDA clearance to begin clinical trials for LY03017, its in-house developed dual-target central nervous system (CNS) drug, the company said in a Monday Hong Kong bourse filing.
The agency also waived the single-ascending-dose requirement, allowing the program to move directly into multiple-ascending-dose testing.
LY03017, intended for Alzheimer's disease psychosis, Parkinson's disease psychosis, and negative symptoms of schizophrenia, is already in a Phase 1 trial in China, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments